Breaking News: Invivyd’s PEMGARDA Continues to Effectively Neutralize Dominant SARS-CoV-2 Variant XEC!
Description:
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those previously reported for KP.3.1.1. The Centers for Disease Control (CDC) estimates that XEC and KP.3.1.1 accounted for an aggregate 69% of U.S. circulating variants of SARS-CoV-2 for the two weeks ended December 21, 2024. Invivyd generated these new data as part of its ongoing industrial virology effort, which leverages a consistent, high-quality, independent, third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based and proprietary analytics.
Blog Post:
As the world continues to grapple with the ongoing challenges posed by the COVID-19 pandemic, the emergence of new variants of the SARS-CoV-2 virus has underscored the importance of developing effective treatments and vaccines. In a groundbreaking development, Invivyd’s PEMGARDA has been shown to effectively neutralize the dominant SARS-CoV-2 variant XEC, offering hope in the fight against the virus.
The continued neutralizing activity of PEMGARDA and pipeline candidate VYD2311 against the XEC variant highlights the potential of these treatments to combat the evolving nature of the virus. With XEC and KP.3.1.1 accounting for a significant portion of circulating variants in the U.S., the data from Invivyd’s research represents a significant step forward in controlling the spread of the virus.
By leveraging a comprehensive virology effort and advanced analytics, Invivyd has demonstrated the effectiveness of PEMGARDA in targeting specific variants of the virus. This breakthrough provides a glimmer of hope in the fight against COVID-19 and showcases the importance of ongoing research and development in the field of biopharmaceuticals.
How this will impact me:
As an individual, the development of treatments like PEMGARDA offers hope for a future where the risks posed by COVID-19 are mitigated. The effectiveness of these treatments against dominant variants of the virus can potentially reduce the impact of the pandemic on personal health and well-being, providing a sense of security and optimism for the future.
How this will impact the world:
The continued success of PEMGARDA in neutralizing the dominant SARS-CoV-2 variant XEC has far-reaching implications for global efforts to combat the pandemic. By targeting specific variants of the virus, treatments like PEMGARDA have the potential to help control the spread of COVID-19 and contribute to the eventual eradication of the virus on a global scale.
Conclusion:
Invivyd’s breakthrough in effectively neutralizing the dominant SARS-CoV-2 variant XEC with PEMGARDA represents a significant milestone in the fight against the COVID-19 pandemic. As individuals and as a global community, the development of targeted treatments like PEMGARDA offers hope for a future where the virus is better controlled and the impacts of the pandemic are mitigated. Continued research and advancements in biopharmaceuticals are essential in our collective efforts to overcome the challenges posed by COVID-19 and ensure a healthier, more secure future for all.
